Subtopic Deep Dive
Cardiovascular Magnetic Resonance in Amyloidosis
Research Guide
What is Cardiovascular Magnetic Resonance in Amyloidosis?
Cardiovascular Magnetic Resonance (CMR) in amyloidosis employs T1 mapping, extracellular volume (ECV) quantification, and late gadolinium enhancement (LGE) to non-invasively assess cardiac amyloid burden, differentiate AL from ATTR types, and predict prognosis.
CMR identifies characteristic subendocardial LGE and elevated native T1 and ECV in cardiac amyloidosis patients. Studies correlate these features with histological amyloid burden and clinical outcomes. Over 10 key papers since 2012, including Fontana et al. (2015, 587 citations) and Dungu et al. (2014, 337 citations), establish CMR's diagnostic and prognostic roles.
Why It Matters
CMR enables non-invasive differentiation of AL and ATTR amyloidosis, guiding therapy selection like chemotherapy for AL or tafamidis for ATTR (Dungu et al., 2014; Fontana et al., 2015). In aortic stenosis cohorts, CMR detects occult amyloidosis linked to worse survival, informing surgical risks (Cavalcante et al., 2016). Expert consensus integrates CMR with nuclear imaging for standardized diagnosis, improving early detection and monitoring treatment response (Dorbala et al., 2019). Prognostic LGE patterns predict mortality, aiding risk stratification in trials (Fontana et al., 2015).
Key Research Challenges
Differentiating AL vs ATTR
CMR features overlap between AL and ATTR, requiring integration with scintigraphy for specificity (Dungu et al., 2014). Native T1 and ECV elevations differ subtly, challenging standalone use (Fontana et al., 2015). Multi-modality consensus addresses this but needs validation (Dorbala et al., 2019).
Quantifying Amyloid Burden
ECV correlates with histology but varies with renal function in AL amyloidosis. LGE extent predicts prognosis yet lacks standardization across vendors (Fontana et al., 2015). Serial CMR for treatment monitoring remains unproven in large cohorts (Banypersad et al., 2012).
Prognostic Model Integration
LGE and T1 predict outcomes independently of NT-proBNP, but composite scores are underdeveloped (Fontana et al., 2015). ATTRwt myths of male predominance complicate CMR screening applicability (González-López et al., 2017). Longitudinal data gaps hinder response assessment (García-Pavía et al., 2021).
Essential Papers
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Marianna Fontana, Silvia Pica, Patricia Réant et al. · 2015 · Circulation · 587 citations
Background— The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac inv...
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging
Sharmila Dorbala, Yukio Ando, Sabahat Bokhari et al. · 2019 · Journal of Nuclear Cardiology · 452 citations
Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths
Esther González-López, Christian Gagliardi, Fernándo Domínguez et al. · 2017 · European Heart Journal · 360 citations
Abstract Aims Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF, and low QRS volt...
CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis
Jason Dungu, Oswaldo Valencia, Jennifer H. Pinney et al. · 2014 · JACC. Cardiovascular imaging · 337 citations
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
Ronald Witteles, Sabahat Bokhari, Thibaud Damy et al. · 2019 · JACC Heart Failure · 323 citations
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive, infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and can often be over...
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases
Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. · 2021 · European Journal of Heart Failure · 315 citations
Abstract Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in th...
Updates in Cardiac Amyloidosis: A Review
Sanjay M Banypersad, James Moon, Carol Whelan et al. · 2012 · Journal of the American Heart Association · 270 citations
Reading Guide
Foundational Papers
Start with Dungu et al. (2014, 337 citations) for AL vs ATTR CMR differentiation via T1/ECV; then Banypersad et al. (2012, 270 citations) for foundational updates on imaging techniques.
Recent Advances
Study Fontana et al. (2015, 587 citations) for LGE prognosis; Dorbala et al. (2019, 452 citations) for multimodality consensus; García-Pavía et al. (2021, 315 citations) for ESC treatment guidelines.
Core Methods
Core techniques: native T1 mapping (elevated >120 ms), ECV (>40%), global subendocardial LGE on phase-sensitive inversion recovery sequences (Fontana et al., 2015; Dungu et al., 2014).
How PapersFlow Helps You Research Cardiovascular Magnetic Resonance in Amyloidosis
Discover & Search
Research Agent uses searchPapers('CMR T1 mapping cardiac amyloidosis') to retrieve Fontana et al. (2015, 587 citations), then citationGraph reveals Dungu et al. (2014) as a key predecessor, and findSimilarPapers expands to Dorbala consensus (2019). exaSearch queries 'ECV quantification ATTR AL differentiation' surfaces 250M+ OpenAlex papers filtered by citations.
Analyze & Verify
Analysis Agent applies readPaperContent on Fontana et al. (2015) to extract LGE prognostic HRs, verifies claims via CoVe against Dorbala et al. (2019) consensus, and runPythonAnalysis on ECV datasets computes statistical significance (p<0.001 for AL vs ATTR). GRADE grading scores Fontana's evidence as high for prognosis.
Synthesize & Write
Synthesis Agent detects gaps in serial CMR monitoring post-tafamidis via contradiction flagging across Banypersad (2012) and García-Pavía (2021), generates exportMermaid flowcharts of diagnostic algorithms. Writing Agent uses latexEditText for methods sections, latexSyncCitations integrates 10+ refs, and latexCompile produces camera-ready reviews.
Use Cases
"Statistical comparison of ECV values in AL vs ATTR amyloidosis from CMR studies"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas meta-analysis on ECV data from Fontana 2015 + Dungu 2014) → researcher gets violin plots and t-test p-values.
"Draft LaTeX review on CMR prognostic value in cardiac amyloidosis"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(10 papers) + latexCompile → researcher gets compiled PDF with LGE survival curves.
"Find code for CMR T1/ECV analysis in amyloidosis papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets validated Python scripts for T1 mapping from linked repos.
Automated Workflows
Deep Research workflow runs systematic review: searchPapers(50+ CMR amyloidosis) → citationGraph clusters AL/ATTR → GRADE all → structured report with ECV meta-analysis. DeepScan applies 7-step CoVe: readPaperContent(Fontana 2015) → verifyResponse vs histology → runPythonAnalysis survival curves. Theorizer generates hypotheses on CMR for tafamidis response from García-Pavía (2021) + Fontana (2015).
Frequently Asked Questions
What is Cardiovascular Magnetic Resonance in amyloidosis?
CMR uses T1 mapping, ECV, and LGE to quantify cardiac amyloid burden non-invasively. It differentiates AL from ATTR via pattern recognition (Dungu et al., 2014).
What are key CMR methods for amyloidosis?
Native T1 mapping detects early infiltration; ECV quantifies amyloid volume; subendocardial LGE assesses transmurality (Fontana et al., 2015; Dorbala et al., 2019).
What are seminal papers on CMR in amyloidosis?
Fontana et al. (2015, Circulation, 587 citations) proves LGE prognostic value; Dungu et al. (2014, JACC Imaging, 337 citations) differentiates AL/ATTR; Dorbala et al. (2019) standardizes multimodality.
What open problems exist in CMR for amyloidosis?
Serial CMR lacks validation for treatment monitoring; vendor standardization needed for T1/ECV; integration with ATTR tracers unoptimized (García-Pavía et al., 2021).
Research Amyloidosis: Diagnosis, Treatment, Outcomes with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiovascular Magnetic Resonance in Amyloidosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers